Kestra Medical CFO Vaseem Mahboob sells $418,217 in shares

Vaseem Mahboob, Chief Financial Officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), sold 18,188 common shares for a total of $418,217 across three transactions between July 30 and August 3, 2026. The shares were sold at prices ranging from $22.6091 to $23.8012.

On July 30, 2026, Mr. Mahboob disposed of 3,980 shares at a weighted average price of $22.7539. The following day, July 31, he sold an additional 8,817 shares at a weighted average price of $22.6091. The final reported transaction occurred on August 3, 2026, with the sale of 5,391 shares at a weighted average price of $23.8012.

These sales represent nondiscretionary transactions required to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. The stock has since appreciated to $28.02, reflecting the company’s strong 74.6% return over the past year despite remaining unprofitable with a market capitalization of $1.63 billion. Following these reported transactions, Mr. Mahboob directly beneficially owns 93,891 common shares of Kestra Medical Technologies, Ltd. According to InvestingPro analysis, KMTS is currently trading near its 52-week high of $30.00, and the platform’s Fair Value assessment suggests the stock may be overvalued at current levels. For investors seeking deeper insights, InvestingPro offers 10 additional exclusive tips, plus comprehensive Pro Research Reports covering KMTS and 1,400+ other US equities.

In other recent news, Kestra Medical Technologies reported a significant increase in revenue for its fiscal fourth quarter of 2026, with a rise of 66% year-over-year to $28.64 million, surpassing the consensus estimate of $26.5 million. Despite this revenue growth, the company reported a larger-than-expected loss, with earnings per share at a loss of $0.67, compared to the forecasted loss of $0.58. Analyst firms have responded to these developments with varied ratings. Stifel reiterated a Buy rating with a $30.00 price target, noting strong growth, while Wolfe Research raised its price target to $30.00, citing better-than-expected execution. Additionally, JPMorgan initiated coverage with an Overweight rating, highlighting the potential of Kestra’s ASSURE wearable cardioverter defibrillator. Oppenheimer, however, started coverage with a Perform rating, pointing to a large addressable market and ongoing market share gains. These developments reflect Kestra Medical’s position in the competitive landscape of wearable medical devices.